SECOND NEOPLASMS IN DIAGNOSTIC PATIENTS OF POLYCYTHEMIA VERA (PV) OR MIELOFIBROSIS (MF) TREATED WITH RUXOLITINIB

被引：0
|
作者：
Sagues Serrano, M. [1 ]
Osca Gelis, G. [2 ]
Lopez Brunso, M. [3 ]
Gonzalez Montes, Y. [1 ]
Buch Villa, J. [1 ]
Diaz Santa, J. [1 ]
Coll Jorda, R. [1 ]
Cruz Garcia, D. [1 ]
Carvajal Nazly, Santos Y. [1 ]
Lloveras Guelque, N. [1 ]
Kelleher, N. [1 ]
Roncero Vidal, J. M. [1 ]
Blanco Blanco, A. B. [1 ]
Mostacedo Marasovic, S. Z. [1 ]
Bustins Tarrats, A. [1 ]
Serrando Querol, M. [4 ]
Jimenez Romero, O. [4 ]
Tuset Andujar, E. [1 ]
Gallardo Giralt, D. [1 ]
机构：
[1] Hosp Univ Girona Dr Josep Trueta, Serv Hematol, ICO Girona, Girona, Spain
[2] Univ Girona, Fac Ciencies Econ & Empresarials, Hosp Univ Girona Dr Josep Trueta, ICO Girona, Girona, Spain
[3] Hosp Univ Girona Dr Josep Trueta, Serv Farm Hosp, ICO Girona, Girona, Spain
[4] Inst Catala Salut, Lab Clin Area Terr Girona, Girona, Spain
来源：
HAEMATOLOGICA | 2019年 / 104卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO-196
引用
收藏
页码：310 / 311
页数：2
相关论文
共 50 条
  • [31] The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis
    Samuelson, Bethany T.
    Vesely, Sara K.
    Chai-Adisaksopha, Chatree
    Scott, Bart L.
    Crowther, Mark
    Garcia, David
    BLOOD COAGULATION & FIBRINOLYSIS, 2016, 27 (06) : 648 - 652
  • [32] SAFETY OF RUXOLITINIB IN PATIENTS WITH POLYCYTHEMIA VERA: RESULTS FROM THE CLINICAL TRIAL PROGRAM
    Verstovsek, S.
    Mesa, R.
    Martino, B.
    Kiladjian, J. -J.
    Jones, M. M.
    He, S.
    Habr, D.
    Alecu, I.
    Vannucchi, A. M.
    HAEMATOLOGICA, 2015, 100 : 263 - 264
  • [33] Effect of durable hematocrit control and minimal thrombotic risk in real-world polycythemia vera patients treated with ruxolitinib
    Chojecki, Aleksander Lech
    Boselli, Danielle
    Dortilus, Allison
    Hamadeh, Issam
    Begley, Stephanie
    Chen, Tommy
    Bose, Rupali
    Podoltsev, Nikolai Alexandrovich
    Zeidan, Amer Methqal
    Balmaceda, Nicole Baranda
    Yacoub, Abdulraheem
    Ai, Jing
    Knight, Thomas Gregory
    Ragon, Brittany K.
    Shah, Nilay Arvind
    Sanikommu, Srinivasa
    Symanowski, James Thomas
    Mesa, Ruben A.
    Grunwald, Michael Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Reversibility of acrocyanosis and improvement of capillaroscopic pattern in a patient with polycythemia vera treated with ruxolitinib: a case report
    Nigro, Angelo
    BLOOD RESEARCH, 2025, 60 (01)
  • [35] Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial
    Gupta, Vikas
    Yacoub, Abdulraheem
    Verstovsek, Srdan
    Mesa, Ruben
    Harrison, Claire
    Vannucchi, Alessandro M.
    Kiladjian, Jean-Jacques
    Deeg, H. Joachim
    Fazal, Salman
    Foltz, Lynda
    Mattison, Ryan J.
    Miller, Carole B.
    Parameswaran, Vinod
    Martin-Regueira, Patricia
    Hernandez, Christopher
    Wang, Jia
    Talpaz, Moshe
    BLOOD, 2022, 140 : 3935 - 3937
  • [36] Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Influences Deregulated Inflammation and Immune Genes in Polycythemia Vera and Allied Neoplasms
    Skov, Vibe
    Riley, Caroline
    Thomassen, Mads
    Kjaer, Lasse
    Larsen, Thomas Stauffer
    Bjerrum, Ole Weis
    Kruse, Torben A.
    Hasselbalch, Hans Carl
    BLOOD, 2018, 132
  • [37] Compassionate Use Program (CUP) with Ruxolitinib in Mexican Patients with Primary Myelofibrosis (PMF), Post - Polycythemia, Vera Myelofibrosis (PPV - MF), and Post Essential Thrombocythemia Myelofibrosis (PET - MF)
    Vargas, Pablo
    Ovilla, Roberto
    Alvarado, Martha
    Lopez, Manuel
    Hurtado Monroy, Rafael
    Carlos Solis, Juan
    Limon, Alejandro
    Agreda, Gladys
    Silva, Salvador
    Julio Kassack, Juan
    Zavala, Saida
    Aguilar, Carlos
    Baez, Enrique
    Barrera, Esperanza
    Osuna, Antonio
    Morales, Javier
    Herrera, Aquileo
    BLOOD, 2012, 120 (21)
  • [38] Ruxolitinib Treatment in Patients With Polycythemia Vera (PV) Reduces JAK2 Allele Burden and Improves Hematocrit Control and Symptom Burden
    Harrison, Claire N.
    Kiladjian, Jean-Jacques
    Palandri, Francesca
    Hamer-Maansson, J. E.
    Braunstein, Evan
    Passamonti, Francesco
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S409 - S409
  • [39] Interim Analysis of a Phase II Pilot Trial of Ruxolitinib Combined with Danazol for Patients with Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET), and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering from Anemia
    Gowin, Krisstina L.
    Dueck, Amylou C.
    Mascarenhas, John O.
    Hoffman, Ronald
    Reeder, Craig B.
    Camoriano, John
    Gano, Katherine
    Ghurye, Vineta
    Reddy, Sravan Nagi
    Koenig, Patricia
    Fauble, Veena
    Tibes, Raoul
    Mesa, Ruben
    BLOOD, 2014, 124 (21)
  • [40] RUXOLITINIB IN PATIENTS WITH POLYCYTHEMIA VERA: IS THERE A DIFFERENCE IN RESPONSES BETWEEN INTOLERANT AND HYDROXYUREA RESISTANT-PATIENTS?
    Gonzalez Perez, E.
    Saez Perdomo, M. N.
    Fernandez Fuertes, F.
    Raya Sanchez, J. M.
    Mayani, K.
    Tapia Torres, M.
    Segura Diaz, A.
    Sanchez Sosa, S.
    Florido Ortega, Y.
    Bilbao Sieyro, C.
    Stuckey, R.
    Molero Labarta, M. T.
    Gomez Casares, M. T.
    HAEMATOLOGICA, 2019, 104 : 309 - 310
12345